• Why the 2002 Women's Health Initiative study was flawed and created decades of HRT concerns

• The timing hypothesis: why age matters when starting hormone replacement therapy

• Synthetic vs. bioidentical hormones and their clinical differences

• Oral estrogen delivery systems and safety implications

• Shared decision-making between patients, prescribers, and pharmacists

• Why compounded HRT solutions matter for patients who don't fit commercial products

• Hormone testing modalities and why multiple testing methods are essential

• Vaginal estrogen's role in preventing UTIs and hip fractures

• How pharmacists can educate providers and patients on HRT safety

In this episode of a Mortar and Pestle, Tenille Davis, Chief Advocacy Officer for the Alliance for Pharmacy Compounding, joins host Mike De Lisio and guest co-host Erin Michael, Director of Member Engagement, to discuss the APC Blue Print, a blueprint for eliminating redundant, unauthorized, or ineffective regulation that impedes patient access to compounded drugs.

Introducing UniFlow.

In this episode of a Mortar and Pestle, Tricia Heitman, PharmD, joins host Mike De Lisio, Vice President of North American Sales, and co-host Sebastian Denison, Clinical Compounding Pharmacist, RPh, FAARM (Candidate) to discuss leucovorin and other supplements for autism.

In this episode of The Mortar & Pestle Podcast, pharmacist and hormone therapy expert Ranel Larsen joins Mike de Lisio, Vice President of North American Sales, and Sebastian Denison, Clinical Compounding Pharmacist, RPh, FAARM (Candidate), to dig into men’s health. From hormone replacement therapy and lab testing to lifestyle factors like stress, sleep, and nutrition, Ranel breaks down how pharmacists can better support male patients while debunking common myths around testosterone.

In this special live episode of Tech Talk, a Mortar & Pestle production, Erin Michael, Director of Member Engagement, is joined by Tiffany Kofroth, CSPT, CPhT-Adv, Advanced Pharmacy Technician in Continuing Pharmacy Education at the University of Texas at MD Anderson Cancer Center from and Mindy Stephens, as they discuss their compounding journeys.

In this episode of The Mortar & Pestle: A PCCA Podcast, host Mike de Lisio is joined by PCCA’s VP of R&D, Daniel Banov, and returning guest Richie Ray, owner of Richie Specialty Pharmacy, to explore the innovation and impact of SubMagna—a proprietary sublingual base developed by PCCA. They discuss the technical challenges and scientific breakthroughs involved in formulating SubMagna to effectively deliver high molecular weight peptides like semaglutide via the sublingual route. Daniel details the base’s development process, including surfactant balancing, solubility enhancement, and permeability optimization, while Richie shares clinical insights, patient responses, and the broader market implications. Together, they highlight SubMagna’s potential as a game-changing delivery system for peptides and other challenging APIs, especially in an era of rising demand for non-injectable therapies.